CA2882303A1 - Multimarker risk stratification - Google Patents
Multimarker risk stratification Download PDFInfo
- Publication number
- CA2882303A1 CA2882303A1 CA2882303A CA2882303A CA2882303A1 CA 2882303 A1 CA2882303 A1 CA 2882303A1 CA 2882303 A CA2882303 A CA 2882303A CA 2882303 A CA2882303 A CA 2882303A CA 2882303 A1 CA2882303 A1 CA 2882303A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- age
- risk score
- multimarker
- mortality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000013517 stratification Methods 0.000 title description 5
- 206010019280 Heart failures Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims description 103
- 230000001965 increasing effect Effects 0.000 claims description 28
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 9
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 7
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 7
- 230000003907 kidney function Effects 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 230000035488 systolic blood pressure Effects 0.000 claims description 7
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 6
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 102400001263 NT-proBNP Human genes 0.000 abstract description 6
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract description 6
- 102000004571 Natriuretic peptide Human genes 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 6
- 239000000692 natriuretic peptide Substances 0.000 abstract description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract description 6
- 238000005259 measurement Methods 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 48
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 46
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 description 43
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 description 42
- 230000015654 memory Effects 0.000 description 35
- 102000004903 Troponin Human genes 0.000 description 24
- 108090001027 Troponin Proteins 0.000 description 24
- 238000012544 monitoring process Methods 0.000 description 20
- 239000003550 marker Substances 0.000 description 18
- 230000000747 cardiac effect Effects 0.000 description 17
- 238000004891 communication Methods 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 14
- 208000029078 coronary artery disease Diseases 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000004590 computer program Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 238000011256 aggressive treatment Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- -1 NTpro-BNP Proteins 0.000 description 2
- 101150095505 ST2 gene Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000009662 stress testing Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100025477 GTP-binding protein Rit1 Human genes 0.000 description 1
- 102100027778 GTP-binding protein Rit2 Human genes 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101001111714 Homo sapiens RING-box protein 2 Proteins 0.000 description 1
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Health & Medical Sciences (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691706P | 2012-08-21 | 2012-08-21 | |
| US61/691,706 | 2012-08-21 | ||
| PCT/US2013/056020 WO2014031764A1 (en) | 2012-08-21 | 2013-08-21 | Multimarker risk stratification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2882303A1 true CA2882303A1 (en) | 2014-02-27 |
Family
ID=50148799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2882303A Abandoned CA2882303A1 (en) | 2012-08-21 | 2013-08-21 | Multimarker risk stratification |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20140058743A1 (forum.php) |
| EP (1) | EP2888687B1 (forum.php) |
| JP (3) | JP6450679B2 (forum.php) |
| CN (2) | CN111834009A (forum.php) |
| AU (3) | AU2013305829A1 (forum.php) |
| CA (1) | CA2882303A1 (forum.php) |
| HK (2) | HK1212057A1 (forum.php) |
| IN (1) | IN2015DN01767A (forum.php) |
| MX (2) | MX375520B (forum.php) |
| RU (1) | RU2015110054A (forum.php) |
| SG (2) | SG10201608854TA (forum.php) |
| WO (1) | WO2014031764A1 (forum.php) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| CN1668763B (zh) | 2002-05-09 | 2012-05-16 | 布赖汉姆妇女医院 | 作为心血管病的标志和治疗靶的il1rl-1 |
| ATE527544T1 (de) | 2006-04-24 | 2011-10-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
| PL2021796T3 (pl) | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| DK2827152T3 (en) | 2008-04-18 | 2016-09-12 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
| MX2012011667A (es) * | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Anticuerpos st-2 humanos solubles y ensayos. |
| EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| MX378293B (es) | 2011-07-18 | 2025-03-10 | Critical Care Diagnostics Inc | Metodos in vitro para correlacionar el nivel de st2 soluble y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular. |
| HK1208624A1 (en) | 2012-05-18 | 2016-03-11 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| IN2015DN01767A (forum.php) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| CN113744876A (zh) * | 2014-01-10 | 2021-12-03 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和系统 |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| CA2996903C (en) | 2015-08-28 | 2024-01-02 | Mcmaster University | Method of determining risk of an adverse cardiac event |
| US20170220749A1 (en) * | 2016-02-01 | 2017-08-03 | MD Aware LLC | Systems and methods for identifying and using medical calculators |
| CN109863404A (zh) * | 2016-04-18 | 2019-06-07 | 豪夫迈·罗氏有限公司 | 用于鉴定一般群体中lvh的进展者的可溶性st2 |
| WO2018220600A1 (en) * | 2017-06-02 | 2018-12-06 | University Of Florida Research Foundation, Inc. | Method and apparatus for prediction of complications after surgery |
| RU2677611C1 (ru) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| EP4640848A2 (en) | 2019-05-17 | 2025-10-29 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| US20220399122A1 (en) * | 2019-11-01 | 2022-12-15 | Nec Corporation | Risk prediction apparatus, risk prediction method, and computer program |
| CN118760892B (zh) * | 2024-09-05 | 2024-11-19 | 温州市中心医院 | 铁死亡评分确定方法、系统及设备 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| JPH0731479Y2 (ja) | 1989-06-02 | 1995-07-19 | 内橋エステック株式会社 | 温度ヒューズ |
| US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| EP0963205A4 (en) | 1996-08-23 | 2002-10-02 | Human Genome Sciences Inc | T1 RECEPTOR TYPE LIGAND II |
| AU6181498A (en) | 1997-02-28 | 1998-09-18 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
| CA2285091A1 (en) | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
| CA2293718A1 (en) | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| US6828107B2 (en) | 1997-09-11 | 2004-12-07 | Shionogi & Co., Ltd. | Immunoassay method for BNP |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
| EP1140137A2 (en) | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
| AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
| EP1311547A2 (en) | 2000-08-22 | 2003-05-21 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of cardiovascular conditions |
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
| FI20010019L (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| AU2002305394A1 (en) | 2001-05-04 | 2002-11-18 | Biosite, Inc. | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
| CN1668763B (zh) | 2002-05-09 | 2012-05-16 | 布赖汉姆妇女医院 | 作为心血管病的标志和治疗靶的il1rl-1 |
| US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
| AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
| US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| WO2005043123A2 (en) | 2003-10-31 | 2005-05-12 | Queststar Medical, Inc. | System and apparatus for body fluid analysis using surface-textured optical materials |
| CA2860272C (en) | 2003-11-26 | 2017-12-19 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| JP4625812B2 (ja) | 2003-12-05 | 2011-02-02 | ザ クリーブランド クリニック ファウンデーション | 心臓血管疾患に対するリスクマーカー |
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| ES2388795T3 (es) | 2005-01-24 | 2012-10-18 | F. Hoffmann-La Roche Ag | Utilización de péptidos de tipo Bnp para la evaluación del riesgo de sufrir insuficiencia cardiaca como consecuencia de la sobrecarga de volumen |
| EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| US20070021977A1 (en) | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
| JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
| ATE527544T1 (de) | 2006-04-24 | 2011-10-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
| EP2021799B1 (en) | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2021796T3 (pl) | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| ES2723957T3 (es) | 2006-05-02 | 2019-09-04 | Critical Care Diagnostics Inc | Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
| CA2554659A1 (en) * | 2006-07-25 | 2006-11-24 | 1128971 Alberta Ltd. | Hanger flange for hanging a tubular body in a well |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| AU2008251801A1 (en) * | 2007-05-11 | 2008-11-20 | The General Hospital Corporation | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
| US20100267062A1 (en) * | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
| WO2009075566A1 (en) * | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| DK2827152T3 (en) * | 2008-04-18 | 2016-09-12 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
| EP2347266B9 (en) * | 2008-11-11 | 2014-02-12 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm |
| WO2011000874A1 (en) * | 2009-07-01 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting cardiovascular mortality risk |
| MX2012005385A (es) * | 2009-11-13 | 2012-09-12 | Bg Medicine Inc | Factores de riesgo y prediccion de infarto al miocardio. |
| US8258456B2 (en) * | 2009-11-27 | 2012-09-04 | Himax Imaging, Inc. | Image sensor |
| MX2012011667A (es) * | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Anticuerpos st-2 humanos solubles y ensayos. |
| CN103328976B (zh) * | 2010-11-01 | 2016-08-10 | B.R.A.H.M.S有限公司 | 具有非特定主诉的患者的预后和风险评估 |
| RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
| EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| MX378293B (es) | 2011-07-18 | 2025-03-10 | Critical Care Diagnostics Inc | Metodos in vitro para correlacionar el nivel de st2 soluble y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular. |
| HK1208624A1 (en) | 2012-05-18 | 2016-03-11 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| IN2015DN01767A (forum.php) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
| CN113744876A (zh) | 2014-01-10 | 2021-12-03 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和系统 |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
| USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2013
- 2013-08-21 IN IN1767DEN2015 patent/IN2015DN01767A/en unknown
- 2013-08-21 RU RU2015110054A patent/RU2015110054A/ru not_active Application Discontinuation
- 2013-08-21 HK HK15112621.5A patent/HK1212057A1/xx unknown
- 2013-08-21 CN CN202010424423.1A patent/CN111834009A/zh active Pending
- 2013-08-21 SG SG10201608854TA patent/SG10201608854TA/en unknown
- 2013-08-21 CN CN201380054795.8A patent/CN104737170A/zh active Pending
- 2013-08-21 WO PCT/US2013/056020 patent/WO2014031764A1/en not_active Ceased
- 2013-08-21 CA CA2882303A patent/CA2882303A1/en not_active Abandoned
- 2013-08-21 US US13/972,596 patent/US20140058743A1/en not_active Abandoned
- 2013-08-21 HK HK15108723.0A patent/HK1208092A1/xx unknown
- 2013-08-21 MX MX2015002254A patent/MX375520B/es active IP Right Grant
- 2013-08-21 AU AU2013305829A patent/AU2013305829A1/en not_active Abandoned
- 2013-08-21 EP EP13831501.5A patent/EP2888687B1/en active Active
- 2013-08-21 JP JP2015528625A patent/JP6450679B2/ja not_active Expired - Fee Related
- 2013-08-21 SG SG11201501271TA patent/SG11201501271TA/en unknown
-
2015
- 2015-02-20 MX MX2020009943A patent/MX2020009943A/es unknown
-
2016
- 2016-12-20 US US15/385,095 patent/US10303844B2/en active Active
-
2018
- 2018-12-10 JP JP2018230514A patent/JP6621520B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-13 AU AU2019201709A patent/AU2019201709B2/en not_active Ceased
- 2019-04-10 US US16/380,513 patent/US10741290B2/en not_active Expired - Fee Related
- 2019-11-19 JP JP2019208375A patent/JP6902083B2/ja not_active Expired - Fee Related
-
2020
- 2020-07-07 US US16/922,580 patent/US20200335220A1/en not_active Abandoned
-
2021
- 2021-04-06 AU AU2021202116A patent/AU2021202116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020009943A (es) | 2020-10-16 |
| SG10201608854TA (en) | 2016-12-29 |
| RU2015110054A (ru) | 2016-10-10 |
| EP2888687A1 (en) | 2015-07-01 |
| AU2019201709A1 (en) | 2019-04-04 |
| AU2019201709B2 (en) | 2021-01-07 |
| US20200335220A1 (en) | 2020-10-22 |
| JP6450679B2 (ja) | 2019-01-09 |
| JP2020034573A (ja) | 2020-03-05 |
| JP2015532715A (ja) | 2015-11-12 |
| IN2015DN01767A (forum.php) | 2015-05-29 |
| SG11201501271TA (en) | 2015-03-30 |
| CN104737170A (zh) | 2015-06-24 |
| MX375520B (es) | 2025-03-06 |
| JP6621520B2 (ja) | 2019-12-18 |
| US10303844B2 (en) | 2019-05-28 |
| US10741290B2 (en) | 2020-08-11 |
| JP2019053086A (ja) | 2019-04-04 |
| EP2888687B1 (en) | 2023-08-02 |
| EP2888687A4 (en) | 2016-04-13 |
| US20140058743A1 (en) | 2014-02-27 |
| JP6902083B2 (ja) | 2021-07-14 |
| AU2013305829A1 (en) | 2015-03-05 |
| WO2014031764A1 (en) | 2014-02-27 |
| CN111834009A (zh) | 2020-10-27 |
| MX2015002254A (es) | 2015-05-08 |
| US20170169179A1 (en) | 2017-06-15 |
| HK1208092A1 (en) | 2016-02-19 |
| HK1212057A1 (en) | 2016-06-03 |
| AU2021202116A1 (en) | 2021-05-06 |
| US20190237197A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10741290B2 (en) | Multimarker risk stratification | |
| JP6788050B2 (ja) | 主要有害心イベントのリスクを予測する方法 | |
| EP2241888B1 (en) | Predicting mortality and detecting severe disease | |
| US11404166B2 (en) | Systems and methods for mining of medical data | |
| Thavendiranathan et al. | Prediction of 30-day heart failure-specific readmission risk by echocardiographic parameters | |
| US11162955B2 (en) | System and method for determining risk of diabetes based on biochemical marker analysis | |
| Michou et al. | Quantifying inflammation using interleukin‐6 for improved phenotyping and risk stratification in acute heart failure | |
| JP7575400B2 (ja) | バイオマーカーに基づく遠隔患者管理の処方 | |
| Huang et al. | Development and validation of a nomogram to predict the risk of death within 1 year in patients with non-ischemic dilated cardiomyopathy: A retrospective cohort study | |
| US20170205420A1 (en) | Biochemical markers for use in determining risk of diabetes | |
| Shengelia et al. | Biomarkers in Heart Failure with reduced Left ventricular ejection fraction, Prognostic significance | |
| Selvan et al. | Echocardiographic Predictors of Readmission and Mortality in Elderly Patients With Heart Failure and Preserved Ejection Fraction: A Prospective Observational Study | |
| CN117711606A (zh) | 一种肺动脉高压预后预测方法、系统及设备 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180808 |
|
| FZDE | Discontinued |
Effective date: 20230104 |
|
| FZDE | Discontinued |
Effective date: 20230104 |